Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Basic Clin Pharmacol Toxicol ; 127(6): 525-532, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32632976

ABSTRACT

Sibutramine is a non-selective serotonin-norepinephrine reuptake inhibitor orally administered for weight loss. In a previous study, we showed pharmacological mechanisms involved in the reduction of sperm quality and fertility of rats exposed for 30 days to this anorexigen in the light phase of the light-dark (l/d) cycle. It is already known that rodents are nightlife animals, with higher metabolic activity during the dark phase than in the light phase of the light-dark (l/d) cycle. Thus, the present study aimed to investigate whether the deleterious effects on reproductive parameters after sibutramine administration would be enhanced after a shorter period of exposure during the dark phase of the l/d cycle. For this, adult male Wistar rats were treated with sibutramine (10 mg/kg/d) or vehicle for 15 days during the dark phase of the l/d cycle. Sibutramine treatment decreased final body and reproductive organ weights, as well as serum testosterone levels. Sperm transit time through the epididymis was accelerated, and sperm concentration and motility were diminished in the sibutramine-exposed rats. The decrease in sperm concentration was also verified in the epididymal histological sections. In conclusion, the deleterious effects of sibutramine on reproductive parameters of male rats were enhanced when the exposure occurred in the dark phase of the l/d cycle, even after a short exposure duration. Our results reinforce the impact of timing on drug therapeutic action.


Subject(s)
Appetite Depressants/toxicity , Cyclobutanes/toxicity , Epididymis/drug effects , Reproduction/drug effects , Spermatozoa/drug effects , Testis/drug effects , Animals , Appetite Depressants/administration & dosage , Cyclobutanes/administration & dosage , Drug Chronotherapy , Epididymis/pathology , Male , Photoperiod , Rats, Wistar , Sperm Count , Sperm Motility/drug effects , Spermatogenesis/drug effects , Spermatozoa/pathology , Testis/pathology , Time Factors
2.
Cell Biol Int ; 42(2): 153-168, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28980742

ABSTRACT

Prostate cancer (PCa) progression mechanism has been linked to epithelial proliferation, tumor invasion ability, and growth factors. Nintedanib (BIBF 1120) has been reported as being FGF and VEGF pathway inhibitors, exhibiting antitumor activity. Thus, the objective herein was to characterize the early Nintedanib treatment effects on the structure and molecules involved in the basal membrane, the extracellular matrix (ECM) maintenance, in addition to the angiogenesis and mitogenic processes at different grades of prostatic tumor development in TRAMP mice. Therefore, 45 male TRAMP mice were divided into control groups: 8-week-old mice (TC8), 12-week-old mice (TC12), and 16-week-old mice (TC16); and treated groups with 10 mg/kg/day Nintedanib dose for 4 weeks. The treated groups were euthanized at 12 (TN12) and 16 (TN16) weeks of age. Samples from the dorsolateral lobe were collected and processed for light microscopy, immunohistochemistry, Western blotting, and microvessel density analysis. The results showed that early Nintedanib treatment led to an increase of healthy epithelium frequency and a reduction of LGPIN and a maximum vascularization density in the TN12 group. Also, treatment led to a well-differentiated adenocarcinoma decrease and an α and ß dystroglycan and also laminin 1 increase in the TN16 group. IGFR1 decreased in the TN16 group. To conclude, early Nintedanib treatment led to a reduction in cancer severity, interfering in both ECM compounds and angiogenesis process to then contribute to a balance, not only in the prostatic epithelium and stroma, but also in the epithelial-stromal interaction during PCa progression.


Subject(s)
Antineoplastic Agents/therapeutic use , Indoles/therapeutic use , Prostatic Neoplasms/drug therapy , Animals , Cell Proliferation/drug effects , Disease Progression , Dystroglycans/analysis , Epithelium/chemistry , Epithelium/pathology , Laminin/analysis , Male , Mice, Transgenic , Prostate/drug effects , Prostate/pathology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Stromal Cells/classification , Stromal Cells/pathology
3.
Toxicology ; 376: 15-22, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-27132128

ABSTRACT

Betamethasone is the drug of choice for antenatal treatment, promoting fetal lung maturation, decreasing the incidence of respiratory distress syndrome and neonatal mortality. Previous studies reported that prenatal treatment with this drug reduced testosterone levels, sperm quality and fertility in adult rats. We aimed to further evaluate the reproductive consequences of prenatal betamethasone exposure in male rats. Pregnant Wistar rats (n=13/group) were separated into two groups: control (vehicle) and betamethasone- treated (0.1mg/kg IM) and rats were injected on gestational days 12, 13, 18 and 19. Body weight, sexual behavior, reproductive organ weights, serum hormone levels, accessory glands contractility, sperm parameters, and fertility after in utero artificial insemination were evaluated. Our results showed that prenatal betamethasone exposure provoked a significant reduction in body weight at PND 01 and, at adulthood, decrease in FSH levels, sperm motility and production. Furthermore, seminal vesicle weight was decreased while testicular and ventral prostate weights were increased. Serum LH levels and the percentage of abnormal sperm were significantly increased. Although sexual behavior was not altered, a significant reduction in fertility in the adult rats exposed prenatally to betamethasone was noted. We concluded that prenatal betamethasone exposure leads to long-term reproductive impairment in male rats. These results may have important implications for humans, considering the use of this glucocorticoid in pregnant women.


Subject(s)
Betamethasone/toxicity , Glucocorticoids/toxicity , Prenatal Exposure Delayed Effects/chemically induced , Reproduction/drug effects , Sexual Behavior, Animal/drug effects , Spermatozoa/drug effects , Animals , Betamethasone/administration & dosage , Dose-Response Relationship, Drug , Female , Glucocorticoids/administration & dosage , Infertility, Male/chemically induced , Infertility, Male/metabolism , Male , Organ Size/drug effects , Organ Size/physiology , Pregnancy , Prenatal Exposure Delayed Effects/metabolism , Rats , Rats, Wistar , Reproduction/physiology , Sexual Behavior, Animal/physiology , Spermatozoa/metabolism , Time Factors
4.
Reprod Toxicol ; 63: 125-34, 2016 08.
Article in English | MEDLINE | ID: mdl-27247242

ABSTRACT

Antenatal betamethasone is used for accelerating fetal lung maturation for women at risk of preterm birth. Altered sperm parameters were reported in adult rats after intrauterine exposure to betamethasone. In this study, male rat offspring were assessed for reproductive development after dam exposure to betamethasone (0.1mg/kg) or vehicle on Days 12, 13, 18 and 19 of pregnancy. The treatment resulted in reduction in the offspring body weight, delay in preputial separation, decreased seminal vesicle weight, testosterone levels and fertility, and increased testicular weight. In the testis, morphologically abnormal seminiferous tubules were observed, characterized by an irregular cell distribution with Sertoli cell that were displaced towards the tubular lumen. These cells expressed both Connexin 43 (Cx43) and Proliferative Nuclear Cell Antigen (PCNA). In conclusion, intrauterine betamethasone treatment appears to promote reproductive programming and impairment of rat sexual development and fertility due to, at least in part, unusual testicular disorders.


Subject(s)
Betamethasone/toxicity , Maternal-Fetal Exchange , Prenatal Exposure Delayed Effects , Sexual Development/drug effects , Animals , Body Weight/drug effects , Connexin 43/metabolism , Female , Fertility/drug effects , Fetal Development/drug effects , Male , Pregnancy , Proliferating Cell Nuclear Antigen/metabolism , Rats, Wistar , Testis/drug effects , Testis/metabolism
5.
J Toxicol Environ Health A ; 77(7): 375-89, 2014.
Article in English | MEDLINE | ID: mdl-24617542

ABSTRACT

Environmental contaminants known as endocrine-disrupting chemicals (EDC) have been associated with adverse effects on reproductive processes. These chemicals may mimic or antagonize endogenous hormones, disrupting reproductive functions. Although preliminary studies focused on environmental estrogens, the presence of compounds with androgenic activity has also been described. This study examines exposure of female pregnant and lactating rats to low doses of androgens and assesses potential effects on female offspring. Pregnant Wistar rats were exposed to testosterone propionate (TP) at doses of 0.05, 0.1, or 0.2 mg/kg or corn oil (vehicle), subcutaneously, to determine influence on reproductive health of female offspring. There were two exposure groups: (1) rats treated from gestational day (GD) 12 until GD 20; and (2) animals treated from GD 12 until the end of lactation. Perinatal exposure to TP produced increased anogenital distance after birth and diminished height of uterine glandular epithelium at puberty in animals exposed to 0.2 mg/kg. However, these alterations were not sufficient to impair sexual differentiation and normal physiology of the female rat reproductive tract.


Subject(s)
Androgens/toxicity , Endocrine Disruptors/toxicity , Environmental Pollutants/toxicity , Lactation , Prenatal Exposure Delayed Effects , Sexual Development/drug effects , Urogenital Abnormalities/chemically induced , Androgens/administration & dosage , Animals , Dose-Response Relationship, Drug , Endocrine Disruptors/administration & dosage , Endometrium/abnormalities , Endometrium/drug effects , Environmental Pollutants/administration & dosage , Female , Fetal Development/drug effects , Injections, Subcutaneous , Maternal Exposure/adverse effects , Pregnancy , Random Allocation , Rats , Rats, Wistar , Teratogens/toxicity , Testosterone Propionate/administration & dosage , Testosterone Propionate/toxicity
6.
PLoS One ; 8(6): e66091, 2013.
Article in English | MEDLINE | ID: mdl-23776614

ABSTRACT

Sperm acquire motility and fertility capacity during epididymal transit, under the control of androgens and sympathetic innervations. It is already known that the acceleration of epididymal sperm transit time can lead to lower sperm quality. In a previous work we showed that rats exposed to the anorexigen sibutramine, a non-selective serotonin-norepinephrine reuptake inhibitor, presented faster sperm transit time, lower epididymal sperm reserves and potentiation of the tension of epididymal duct to norepinephrine exposed acutely in vitro to sibutramine. In the present work we aimed to further investigate pharmacological mechanisms involved in these alterations and the impact on rat sperm quality. For this, adult male Wistar rats were treated with sibutramine (10 mg/kg/day) or vehicle for 30 days. Sibutramine decreased final body, seminal vesicle, ventral prostate and epididymal weights, as well as sperm transit time in the epididymal cauda. On the contrary of the in vitro pharmacological assays, in which sibutramine was added directly to the bath containing strips of distal epididymal cauda, the ductal tension was not altered after in vivo sub-chronic exposure to sibutramine. However, there is pharmacological evidence that the endogenous epididymal norepinephrine reserves were reduced in these animals. It was also shown that the decrease in prostate weight can be related to increased tension developed of the gland, due to sibutramine sympathomimetic effects. In addition, our results showed reduced sperm quality after in utero artificial insemination, a more sensitive procedure to assess fertility in rodents. The epididymal norepinephrine depletion exerted by sibutramine, associated with decreases in sperm transit time, quantity and quality, leading to reduced fertility in this experimental model, reinforces the concerns about the possible impact on fertility of man taking sibutramine as well as other non-selective serotonin-norepinephrine reuptake inhibitors, especially considering the lower reproductive efficiency of humans compared to males of other species.


Subject(s)
Appetite Depressants/pharmacology , Body Weight/drug effects , Cyclobutanes/pharmacology , Fertility/drug effects , Spermatozoa/drug effects , Analysis of Variance , Animals , Fertility/physiology , Follicle Stimulating Hormone/blood , Genitalia, Male/anatomy & histology , Genitalia, Male/drug effects , Luteinizing Hormone/blood , Male , Organ Size/drug effects , Rats , Rats, Wistar , Sperm Motility/drug effects , Spermatozoa/physiology , Testosterone/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...